CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO
Levetiracetam Effective at Controlling Seizures During Pregnancy
In the July 3, 2014, on-line edition of the journal Epilepsia, researchers at the University of Melbourne showed that levetiracetam (Keppra®), a second generation antiepileptic drug (AED), appears as efficacious as first generation AEDs in controlling seizure occurrences among pregnant women. The researchers reported that levetiracetam was also associated with greater seizure control than second generation AEDs such as lamotrigine (Lamictal®) and topiramate (Topamax®) (The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy).
 
Using a national registry, the researchers analyzed seizure control data from over 1,000 pregnancies between the middle of 1998 and November, 2013. Patients took only one AED for at least the first trimester. The data showed that seizure occurrence rates for patients who took only levetiracetam were 31.7% for any seizure and 13.4% for convulsive seizures, which were comparable to rates of first generation AEDs, such as carbamazepine and valproate (34.8% for any seizure and 13.4% for convulsive seizures). Seizure occurrence rates for patients administered second generation AEDs such as lamotrigine and topiramate were found to be higher (50% for any seizure and 30% for convulsive seizures) than patients on levetiracetam monotherapy.
 
This finding, according to the authors, supports the use of levetiracetam as a first choice therapeutic in women with seizure disorder who have the potential for pregnancy or who are pregnant. The authors noted some limitations with the study, including the inability to guarantee that drugs were taken as prescribed and that the allocation of particular AEDs was not randomized.
 
Cerilliant offers certified reference standards of levetiracetam, topiramate, and lamotrigine as well as their native and stable-labeled internal standards. In addition, Cerilliant provides a wide selection of first and second generation antiepileptics including native and stable-labeled internal standards of pregabalin, lacosamide, gabapentin, zonisamide, valproic acid, felbamate, carbamazepine and oxcarbazepine. These reference solutions are manufactured and certified to the highest industry standards including ISO 13485, ISO Guide 34, and ISO/IEC 17025 and are classified as "certified reference materials" in accordance with ISO requirements. Click on the link below to view our comprehensive listing of reference solutions for first and second generation antiepileptics:
 
 


Return to Article List


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn